SOLV's Q3 Earnings: Can Growth Momentum Offset ERP-Related Headwinds?

Zacks
Öffnen unter Zacks
SOLV's Q3 Earnings: Can Growth Momentum Offset ERP-Related Headwinds?

Solventum Corporation SOLV is scheduled to report third-quarter 2026 results on Nov. 5, after market close. The quarterly results are likely to reflect continued growth across MedSurg and Dental, supported by strong commercial execution, product innovation and increasing adoption of key growth drivers. However, the reversal of Q2’s ERP-related advance orders, ongoing implementation challenges and tariff pressures are expected to have weighed on reported growth and margins.

Investors will closely monitor organic sales growth, ERP-related order normalization, margin trends and Acera’s growth momentum. Management’s commentary on the HIS separation, completion of the 3M separation and progress toward its long-term growth and profitability targets will also be key.

Over the past three-month period, SOLV shares declined 7.7%, underperforming the Zacks Medical Services industry and the S&P 500 Index, which advanced 10% and declined 1.9%, respectively.

Zacks Investment Research
Image Source: Zacks Investment Research

SOLV’s Earnings Surprise History

SOLV beat on earnings in all the trailing four quarters, delivering an average surprise of 13.18%.

Zacks Investment Research
Image Source: Zacks Investment Research

SOLV’s Q3 Consensus Estimate

The Zacks Consensus Estimate for third-quarter earnings is pinned at $1.38 per share, indicating a decline of 8%. The earnings estimate has remained unchanged over the past seven days. The consensus estimate for revenues is pinned at $1.97 billion, suggesting 6% year-over-year decline.

Quarterly Drivers

Strong MedSurg and Dental Momentum: Solventum’s MedSurg and Dental businesses are expected to have remained key growth drivers, supported by improving commercial execution, product innovation and increasing adoption of differentiated solutions. Acera’s strong momentum, evident from the second-quarter sales growth of 48%, and continued demand for advanced wound care and dental products are likely to have supported underlying performance in the third quarter.

Innovation and Growth Driver Adoption: Increasing penetration of higher-value solutions across IV site management, advanced wound care and dental aesthetics is likely to have supported sales growth. Recent product launches, including V.A.C. Peel and Place and new Attest sterilization products, along with Acera’s differentiated Restrata technology, are likely to have contributed to customer conversions and revenue momentum.

Challenges

ERP-Related Order Reversal: The reversal of approximately $125 million in ERP-related advance orders recorded in the second quarter is expected to have weighed on third-quarter reported sales. Management indicated that this reversal could result in a 3-4% decline in sales growth, making inventory replenishment and the successful execution of the final ERP cutover critical to limiting further disruption.

Tariff and Inflationary Pressures: Margin performance is likely to remain under pressure from tariffs, inflation and ongoing transformation-related costs. Second-quarter gross margin, excluding the $100 million tariff refund, declined 40 basis points year over year, reflecting tariff and inflation headwinds. The absence of a similar tariff refund benefit in the third quarter could also weigh on year-over-year earnings comparisons.

Solventum Corporation Price and EPS Surprise

Solventum Corporation Price and EPS Surprise

Solventum Corporation price-eps-surprise | Solventum Corporation Quote

What Our Model Unveils for Solventum Stock

Our proven model predicts an earnings beat for SOLV this earnings season. The combination of a positive Earnings ESP and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. That is exactly the case here, as you can see below.

Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is +10.15%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

Zacks Rank: SOLV has a Zacks Rank #3 at present.

Other Stocks to Consider

Some other top-ranked stocks worth considering from the broader medical space are Glaukos GKOS, Edward Lifesciences EW and Globus Medical GMED, each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Glaukos reported second-quarter 2026 earnings per share (EPS) of 14 cents, which beat the Zacks Consensus Estimate by 50.00%. Revenues of $186 million surpassed the Zacks Consensus Estimate by 24.1%.

Glaukos has an estimated earnings growth rate of 268.8% for 2027. GKOS’ earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 25.87%.

Edward Lifesciences reported second-quarter 2026 adjusted EPS of 78 cents, which beat the Zacks Consensus Estimate by 6.85%. Revenues of $1.74 billion surpassed the Zacks Consensus Estimate by 2.45%.

Edward Lifesciences has an estimated long-term earnings growth rate of 12.7%. EW’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 4.49%.

Globus Medical reported a second-quarter fiscal 2026 adjusted EPS of $1.34, which beat the Zacks Consensus Estimate by 19.6%. Revenues of $790 million missed the Zacks Consensus Estimate by 0.35%.

Globus Medical has an estimated long-term earnings growth rate of 12.4%. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.88%.

Radical New Technology Could Hand Investors Huge Gains

Quantum Computing is the next technological revolution, and it could be even more advanced than AI.

While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.

Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .

Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.

See Top Quantum Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Solventum Corporation (SOLV): Free Stock Analysis Report
 
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
 
Globus Medical, Inc. (GMED): Free Stock Analysis Report
 
Glaukos Corporation (GKOS): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research